Cefadog

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefadog

Property Description
Active ingredient Cephalexin (Cephalexinum monohydricum)
Form Tablets, Capsules, Oral Powder for Reconstitution
Pharmacological Class First-generation cephalosporin antibiotic
Common Use Elimination of susceptible bacterial infections
Origin Semisynthetic compound

What Type of Drug is Cefadog?

Cefadog is a veterinary medication whose active component, Cephalexin, is a semisynthetic antibiotic belonging to the cephalosporin family, specifically classified as a first-generation cephalosporin. This classification reflects its established utility in clinical practice and its efficacy against common bacterial species. The primary, high-level purpose of this medication is to function as an effective antimicrobial agent, designed to combat and eliminate susceptible bacterial infections.

This drug serves as a reliable defense against a broad spectrum of common bacteria, particularly those known as gram-positive cocci, which frequently cause infections of the skin, soft tissues, and urinary tract. A typical use scenario involves targeting skin infections (pyoderma) in dogs caused by susceptible organisms. Being a first-generation cephalosporin ensures a well-understood pharmacological profile and strong activity, making it a reliable choice for managing acute bacterial infections.


Composition and Form: Cephalexin and Dosage Type

The sole active ingredient in Cefadog is Cephalexin (often present as Cephalexinum monohydricum), confirming it as a single active ingredient product. This medication is formulated for oral administration and is typically supplied in solid drug forms, such as tablets (frequently scored tablets) or capsules, or as an oral powder for reconstitution into a liquid solution. Cefadog is commercially differentiated by being specifically marketed and formulated for its primary target audience, which is veterinary patients, specifically dogs (Canis).

The product is uniquely positioned through its available high-dose, quadri-scored tablets (e.g., Cefadog 300 quadri or Cefadog 750 quadri), designed to allow for flexible and accurate dosing tailored to various canine weights. This feature, along with the convenience of oral administration, ensures the delivery of the antimicrobial compound required to eliminate the underlying bacterial infections via a convenient, non-invasive method.


How Does Cefadog Work at a High Level?

Cefadog works by exerting a powerful bactericidal action, meaning it actively kills the bacteria responsible for the illness rather than just inhibiting their growth. This definitive action is achieved through a targeted interference with the structure of the bacterial cell. The drug operates by causing the structural breakdown of the protective bacterial cell wall, an essential outer layer required for the organism's viability. The drug's beta-lactam structure is key to this targeted interference, which results in the failure of the bacterial cell and allows the body to eliminate the source of the bacterial infection. This mechanism makes the semisynthetic Cephalexin a potent and reliable tool for achieving microbial clearance.

Regulatory References

  1. Cephalosporins

What side effects are possible with Cefadog?

Possible Side Effects and Safety Information

The official regulatory profile for Cefadog, containing the active ingredient Cephalexin, details possible adverse reactions classified by frequency and the body system affected. These classifications ensure transparency regarding the risk profile documented from clinical use and post-marketing surveillance.


Adverse Reaction Categories

Adverse effects are documented across several System-Organ Classes. The most frequently reported effects are generally Gastrointestinal Disturbances, including nausea, vomiting, abdominal pain, and diarrhea, which is classified as a common adverse reaction in regulatory documents. Other systems affected include the Skin and Subcutaneous Tissue (e.g., rash, urticaria) and the Nervous System (e.g., headache, dizziness).


Serious Adverse Reactions and Safety Restrictions

Official labeling identifies specific serious adverse reactions. These include severe hypersensitivity reactions such as anaphylaxis, which requires immediate attention. Another documented risk is Clostridioides difficile-Associated Diarrhea (CDAD), which can range from mild diarrhea to severe colitis and may occur during or up to two months after the course of treatment. Rare hematologic effects like neutropenia and kidney complications like interstitial nephritis have also been reported.


Population and Exposure Safety Notes

The medicine is subject to safety restrictions. It is officially contraindicated for individuals with a known allergy to any antibiotic in the cephalosporin class and caution is advised for those with a history of penicillin allergy due to the documented potential for cross-hypersensitivity. Individuals with impaired renal function require specific consideration, as the delayed clearance of Cephalexin in this group increases the potential for adverse effects. Prolonged use may result in superinfection from the overgrowth of non-susceptible organisms, which is a known pattern for broad-spectrum antibiotics.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation on Cephalexin (the active ingredient in Cefadog) defines the overdose profile based on gastrointestinal symptoms and the potential for severe Central Nervous System ( CNS) effects.

Property Official Regulatory Statement
Documented Overdose Manifestations Symptoms may include Nausea, Vomiting, Epigastric distress, Diarrhea, and transient Hematuria (bloody urine).
Serious Outcomes The potential for Convulsions or Seizures is a documented serious outcome, particularly with massive ingestion.
Population-Specific Note The risk of severe CNS effects is heightened in patients with pre-existing renal impairment due to the drug's accumulation.

Official regulatory guidance requires immediate action for any suspected overdose.

Action Official Regulatory Mandate
Immediate Help Required Seek immediate medical attention or contact emergency services for any known or suspected overdose due to the potential for severe manifestations.
Antidote Information No specific antidote is known for Cephalexin overdose.
Management Measures Management is limited to symptomatic and supportive treatment. The drug is noted as being dialyzable, a procedural consideration for massive overdose management.

These official statements define the required emergency protocol, emphasizing that while overdose may present with common GI upset, the mandatory action is to seek immediate professional medical consultation to mitigate the documented risk of severe neurological complications, especially in vulnerable patients.

Therapeutic Uses of Cefadog

The primary role of Cefadog is providing short-term symptomatic assistance by addressing underlying bacterial issues. The medication is applied in clinical settings that involve acute or unstable symptom patterns caused by susceptible bacteria, and supports patients during difficult episodes by easing distress.

The active ingredient is used to address the symptomatic discomfort associated with bacterial skin infections like superficial pyoderma in dogs.

Cefadog is commonly used across conditions presenting with acute episodes that are rooted in bacterial infection. Therapeutic domains include the management of bacterial skin infections (pyoderma), urinary tract infections (UTIs), and infections linked to organ-specific functional stress.

“This treatment is used in situations involving certain distressing symptoms and provides support during episodes of heightened discomfort.”

Therapeutic Focus on Inflammatory States and Discomfort

This antibiotic is applied across domains where additional symptomatic support is needed, particularly for symptoms related to inflammatory or irritative states, such as discharge, crusting, swelling, and subsequent discomfort. Cefadog contributes to improved comfort and supports skin health during periods of heightened symptoms. Beyond dermatological use, it assists with maintaining functional stability when symptoms linked to organ-specific functional stress are present.

Quick Fact: Support for Conditions Marked by Irritative States

Regulatory References

  1. RILEXINE® (cephalexin tablets) Chewable Tablets - DailyMed

Eligibility and Restrictions for Use

Contraindications and Non-Eligibility

The medicine is strictly contraindicated in any patient with a known hypersensitivity or allergy to its active substance, cephalexin, or to related antibacterial drugs. This absolute exclusion specifically extends to patients with an allergy to any antibiotic belonging to the beta-lactam class, which includes penicillins and other cephalosporins. Furthermore, this veterinary product is exclusively for use in the target species, dogs, and is not for use in humans. Its administration is legally restricted to be by or on the order of a licensed veterinarian.


Conditional Use and Reproductive Restrictions

Eligibility is conditional for patients presenting with certain comorbidities. The drug must be administered with caution in patients with markedly impaired renal function (severe kidney disease), as regulatory guidance identifies this as a population requiring special consideration. Similar caution is advised for animals with a history of gastrointestinal disease, such as colitis.

Use is defined as safety not established in specific reproductive populations. This regulatory classification limits eligibility and applies to pregnant females, lactating females, and breeding males, due to a lack of formal safety data in these groups.

What should I know about interactions with other medicines?

The official interaction profile for Cephalexin (the active ingredient in Cefadog) is primarily defined by pharmacokinetic interference related to renal clearance and specific absorption constraints. Co-administration of Cephalexin with certain medicines and products may alter the plasma concentrations of either agent.


Transporter-Mediated Drug Interactions

The co-administration of Probenecid is documented to inhibit the active renal excretion of Cephalexin. This pharmacokinetic interaction results in an increased systemic exposure and higher plasma concentrations of Cephalexin. Conversely, Cephalexin itself is noted to interfere with the clearance of Metformin by inhibiting its active renal tubular secretion. This effect officially leads to an increase in Metformin's systemic exposure, specifically increasing its mean plasma concentration (Cmax) by 34% and its Area Under the Curve (AUC) by 24%.


Interactions with Supplements and Administration Timing

A timing-based restriction is formally documented for mineral supplements. Due to the risk of reduced Cephalexin absorption, products containing zinc must be administered with a mandatory separation of at least three hours from Cephalexin. The product may otherwise be taken without regard to meals.


Interference with Diagnostic Tests

Administration of Cephalexin is documented to cause a false-positive reaction for glucose in the urine when tested using non-enzymatic methods, such as those employing Benedict's or Fehling's solutions.

Mechanism of Action

Molecular Targeting of Cell Wall Enzymes

The mechanism of action of Cephalexin functions by disrupting the structural integrity of the bacterial cell wall, a process defined as bactericidal action. The core action involves the covalent inhibition of bacterial enzymes called Penicillin-Binding Proteins (PBPs), which are located on the inner cell membrane.

These PBPs are critical for the transpeptidation step, the final stage in building the bacterial cell wall's protective peptidoglycan layer. By forming a stable chemical bond with the PBP, Cephalexin halts the structural cross-linking process. The mechanism selectively targets enzymatic pathways unique to the bacterial cell.

Triggering of Osmotic Lysis

The resulting failure of cell wall assembly results in structural weakness of the bacterial cell against internal pressure (turgor). This structural compromise initiates an autolytic cascade that culminates in osmotic lysis, causing the cell to rupture and die. The resulting cellular breakdown process generates the osmotic lysis effect, leading to the inactivation of the bacterial cell population.

Dosage and Administration Information

How Cefadog is Used

The administration of Cefadog is structured by usage instructions that define the precise route, dosage calculation, and duration of the course for its active ingredient, Cephalexin.

Official Administration Guidelines

Usage Component Official Labeled Instruction
Route of Administration The only approved method of delivery is oral administration.
Dosing Schedule Dosing is weight-dependent, requiring a calculation of 22 mg per kilogram (kg) of body weight (or 10 mg per pound (lb)).
Frequency The medicine must be administered twice daily (BID) to maintain adequate levels as outlined in official protocols.
Course Duration The standard course is for a fixed duration of 28 days when addressing susceptible bacterial skin infections.
Administration Timing Cefadog may be administered with or without food; the extent of drug absorption is not substantially affected by the presence of food.

Procedural Structure

The standard procedure requires the initial calculation of the dose based on the patient’s exact weight to ensure the correct amount is delivered, following the 22 mg/kg regimen. This calculated dose is then administered orally two times per day. This protocol is intended to be maintained consistently for the full 28-day short-term course to adhere to the standardized use defined by regulatory documents.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cefadog

Evidence for Use in Bacterial Skin Infections (Pyoderma)

The clinical evidence base for Cefadog (Cephalexin) in bacterial skin infections, such as pyoderma, includes data from Randomized Controlled Trials (RCTs) and controlled field studies. These research scenarios involved short-term evaluation of individuals with conditions associated with acute or disruptive episodes of skin infection. Studies monitored populations diagnosed with either superficial or deep pyoderma to observe how symptoms evolved during the study period.

These studies were designed to measure changes related to clinical outcomes using established scoring systems for assessing lesion severity (e.g., redness, crusting) and physical discomfort. Furthermore, research examined the rate of bacteriological clearance—that is, the confirmation of whether the target bacteria were eliminated from the site. Research describes patterns measured during the study period related to these clinical and bacteriological outcomes taken over defined time intervals.

Study Focus: Comparing Treatments and Measuring Clearance

The evidence base includes trials that examined outcomes when Cefadog was studied alongside other existing antimicrobial approaches. These trials are designed to explore comparative differences between two approaches. Evidence from these studies contributes to the broader evidence landscape by providing context on how clearance of susceptible bacteria was measured and reported. Research highlights changes in measured physical discomfort during the study period.


Durability of Response and Long-Term Follow-up Studies

Research has also monitored responses beyond the initial treatment phase, particularly for patient groups with conditions characterized by fluctuating or episodic manifestations. However, existing studies provide limited information for long-term outcomes, particularly concerning the durability of bacteriological clearance over time. Follow-up durations were limited in many studies.


What is Still Uncertain About Cefadog's Evidence Base

For many acute indications, follow-up durations were limited, and the evidence largely covers immediate post-treatment clearance. Furthermore, evidence quality varies across studies, and some comparative evidence is lacking, as many trials compare the drug to other active antibiotics. This research highlights what is known—and what is still uncertain—about Cefadog. Research is ongoing to address these gaps and provide a more comprehensive understanding of the evidence landscape across various clinical settings.

Key Studies & References

  1. RILEXINE® (cephalexin tablets) Chewable Tablets - FDA DailyMed Label
  2. Cephalexin Monograph - MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Cefadog (FAQ)

Q: How quickly does Cefadog usually start working?

A: Studies and official pharmacokinetic data indicate that the active ingredient is rapidly absorbed into the body. Average peak concentrations in the bloodstream, which is an important measure of drug availability, are typically reached around one hour after the dose is administered.

Q: Is Cefadog safe to use during pregnancy, according to official documents?

A: Regulatory documents classify the use of this medication in pregnant females as safety not established. This classification is due to a lack of formal safety data specifically for this population, and use in this population requires specific consideration.

Q: What official warnings are there for using Cefadog while breastfeeding?

A: The use of this medication in lactating females is also classified in official documents as safety not established. This status reflects that formal safety data for the use of the active ingredient during this period are not available.

Q: Is Cefadog available in different forms, like liquid or injection?

A: The medication is formulated for oral administration and is supplied as tablets, capsules, or a powder that is reconstituted into a liquid suspension. An injectable form is not typically listed among the officially supplied dosage types.

Q: Can elderly patients use Cefadog?

A: Regulatory information advises caution when the medicine is used in patients with impaired renal function (kidney issues). Due to the potential for delayed drug clearance, special consideration is given to patients with impaired kidney function.

Q: Why do official documents mention kidney function when describing Cefadog use?

A: Kidney function is mentioned because the active ingredient is primarily eliminated from the body by the kidneys through a process called renal excretion. If kidney function is compromised, this process is delayed, which can increase the potential for adverse effects.

Q: What are the most serious possible side effects listed for Cefadog?

A: Official labeling identifies specific serious reactions that include severe hypersensitivity reactions (anaphylaxis) and serious bowel conditions like Clostridioides difficile-Associated Diarrhea (CDAD).

Q: Does Cefadog have a risk of causing allergic reactions?

A: Yes, official documents detail the risk of hypersensitivity reactions (allergic reactions), including severe reactions. The medicine is contraindicated for those with a known allergy to the cephalosporin class of antibiotics.

Q: Is Cefadog effective against MRSA?

A: No, the official drug label and supporting evidence explicitly indicate that the medication is ineffective against Methicillin-resistant Staphylococcus aureus (MRSA). The medication's label information indicates it is typically not recommended for use when MRSA is suspected or confirmed.

Q: Why is it important to finish the entire prescribed amount of Cefadog?

A: Regulatory guidance stresses the importance of completing the full course of treatment as prescribed. Completing the full course supports bacteriological clearance and contributes to minimizing the risk of developing drug-resistant bacteria.

Q: What is the difference between Cefadog and Amoxicillin?

A: According to official classifications, the active ingredient in Cefadog (Cephalexin) belongs to the cephalosporin class of antibiotics. Amoxicillin, however, belongs to the penicillin class. Both fall under the broader beta-lactam antibiotic family.

Q: Is Cefadog a widely researched medicine?

A: Yes, the clinical evidence base for the active ingredient is substantial and includes data from both controlled studies and Randomized Controlled Trials (RCTs). These studies examine outcomes like clinical signs and bacteriological clearance.

Q: How long does Cefadog stay in my system after the last dose?

A: Pharmacokinetic data suggests that following oral administration, the active ingredient is generally characterized by a relatively rapid elimination from the body. It is primarily cleared through the kidneys.

Q: Can Cefadog cause sleepiness or drowsiness?

A: Official lists of potential side effects include effects on the central nervous system. These may manifest as extreme tiredness (fatigue) and dizziness.

Q: Is it common to have diarrhea while taking Cefadog?

A: Yes, official regulatory documents classify diarrhea as a common gastrointestinal adverse reaction. This is one of the most frequently reported side effects associated with the use of the medication.

Q: Can Cefadog affect birth control pills?

A: Official patient information suggests that the active ingredient does not stop hormonal contraception from working. However, if the medication causes severe diarrhea that lasts for an extended period, the protection provided by oral contraceptives may be lessened.

Q: What should I do if I miss a dose of Cefadog?

A: Official instructions typically outline a procedure for a missed dose, generally focusing on taking it promptly unless the next dose is due, without taking a double dose. Specific protocols are defined in the administration instructions.

Q: Can Cefadog interfere with laboratory test results?

A: Yes, official documentation warns that the medication is known to cause a false-positive reaction for glucose in the urine when certain non-enzymatic testing methods are used. The need to inform healthcare providers about its use is noted prior to certain lab work.

Q: Does Cefadog need to be refrigerated?

A: The storage requirement depends on the form: tablets and capsules should be stored at room temperature. However, the liquid suspension (once prepared by reconstitution) must be kept in a refrigerator and must be discarded after the designated period.

Q: Can Cefadog cause changes in mood or anxiety levels?

A: Official lists of potential side effects include effects on the nervous system. These documented central nervous system effects include reports of agitation and confusion.

Q: Can Cefadog be used for viral infections like the common cold?

A: No. Official documents confirm that the active ingredient is an antibiotic designed to eliminate bacterial infections. Antibiotics, by their nature, are not effective against viral infections such as the common cold or flu.

Q: Does Cefadog have any potential interactions with vitamins or supplements?

A: Yes, official labeling notes that the medication is known to interact with zinc supplements, which must be taken at least three hours apart. Official information does not confirm the safety profile for many other vitamins, herbal remedies, or supplements.

Q: What official information is available about long-term use of Cefadog?

A: Research provides limited information concerning long-term effects. However, it is documented that prolonged use carries a risk of superinfection from the overgrowth of non-susceptible organisms.

Q: Can people with a known history of epilepsy take Cefadog?

A: Official warnings state that drugs in the cephalosporin class have been implicated in triggering seizures. This risk is mentioned particularly for patients with pre-existing conditions like a history of epilepsy or impaired renal function.

Q: Is it true that Cefadog can sometimes cause yeast infections?

A: Yes, the risk of superinfection mentioned in official documents includes the potential for the overgrowth of non-susceptible organisms. This can result in localized infections such as yeast infections (like oral thrush or vaginal yeast infections).

Q: Can Cefadog be used to prevent infections?

A: Yes, in specific medical scenarios, the active ingredient is described in authoritative sources as being used to prevent certain bacterial infections. Examples include the prevention of bacterial endocarditis or recurrent urinary tract infections.

Q: What is the maximum duration of treatment with Cefadog usually described in official materials?

A: The standard course duration for susceptible bacterial skin infections, as defined by the core regulatory documents for this product, is a fixed duration of 28 days. The overall duration of treatment is defined by the specific condition being addressed.

Q: Are there any studies comparing Cefadog to placebo for its main use?

A: Research evidence includes trials that have examined outcomes when the medicine was studied alongside other active antimicrobial approaches. Official documents acknowledge that certain comparative data or evidence of high quality may be lacking depending on the specific trial.

Q: How is Cefadog eliminated from the body?

A: The active ingredient in the medication is primarily eliminated from the body by the kidneys. This process is known as active renal excretion and is the main way the drug leaves the system.

Q: Is Cefadog a Schedule drug or controlled substance?

A: Official classification documents confirm that the active ingredient, Cephalexin, is not designated as a controlled substance or Schedule drug under current regulations.

Q: Is Cefadog used in veterinary medicine too?

A: Yes, the product Cefadog is specifically formulated and marketed for use in veterinary medicine. The primary target audience for this regulated product is dogs.

Q: Is the evidence for Cefadog based on animal studies or human trials?

A: Research evidence includes controlled studies involving the target species, dogs, addressing clinical outcomes like lesion severity. This is complemented by a substantial body of evidence derived from human clinical use of the active ingredient.

Q: Can Cefadog be split or crushed?

A: The solid drug form is often supplied as quadri-scored tablets, which means the tablet has score lines that indicate it can be broken into smaller portions to allow for administration flexibility.

Q: Is Cefadog safe to take with alcohol?

A: Authoritative sources indicate that while a severe, life-threatening interaction is not generally expected, consuming alcohol may potentially worsen common side effects such as nausea and stomach upset.

Q: Why do some people experience stomach upset when taking Cefadog?

A: Gastrointestinal Disturbances, including nausea, vomiting, and abdominal pain, are documented in official safety information. These are the most frequently reported adverse effects associated with the medication's use.

How should Cefadog be stored and disposed of?

How to Store and Dispose of Cefadog?

The official storage requirements for Cefadog are determined by the medication's form. Tablets and capsules must be stored at a Controlled Room Temperature (20 C to 25 C), protected from light and excessive moisture. The product must be kept in its original, tightly closed container.


If the medicine is an oral powder for suspension, the liquid, once reconstituted, must be stored in a refrigerator and discarded after 14 days.

All forms must be stored out of the sight and reach of children and pets.


Disposal instructions mandate that unused or expired product should be disposed of according to local regulations. The medication must not be disposed of via wastewater (flushing down the toilet or pouring down the sink) unless explicitly instructed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefadog found in:

A-Z Index: